Welcome to our dedicated page for Silo Pharma news (Ticker: SILO), a resource for investors and traders seeking the latest updates and insights on Silo Pharma stock.
Silo Pharma, Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company committed to merging traditional therapeutics with psychedelic research to address a variety of underserved conditions. The company's focus spans post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer's disease, Parkinson's disease, and other rare neurological disorders.
Silo's mission is to identify and license transformative assets, funding cutting-edge research to enhance patient well-being and advance the healthcare industry. Recent achievements include the filing of a provisional patent for SP-26, a ketamine-based implant for chronic pain management, and the exclusive licensing of SPC-15 from Columbia University, a novel intranasal treatment for PTSD and anxiety.
Core Business and Projects
- SPC-15: An intranasal treatment targeting PTSD and stress-induced anxiety disorders. Silo has exercised its option to license SPC-15 from Columbia University, with preclinical studies showing promising results.
- SP-26: A time-release, ketamine-loaded implant aimed at fibromyalgia and chronic pain relief. The implant has shown positive results in pre-clinical studies and is expected to be the first at-home approved ketamine-based therapeutic if it passes clinical trials.
- SPC-14: An intranasal compound for the treatment of Alzheimer's disease, showing potential in preclinical studies for improving cognitive function and stress reduction.
- SPU-16: A CNS-homing peptide targeting multiple sclerosis (MS), developed in collaboration with the University of Maryland, Baltimore.
Silo's innovative approach combines traditional therapies with psychedelic treatments, aiming to develop novel formulations and drug delivery systems. The company's robust pipeline and strategic partnerships with leading medical universities position Silo at the forefront of biopharmaceutical advancements.
Financial Condition and Partnerships
Silo Pharma collaborates extensively with Columbia University and the University of Maryland, Baltimore, providing essential financial resources to advance their research from the clinical stage to commercialization. The company is financially positioned to support ongoing and future projects that could significantly impact the medical and psychedelic treatment landscape.
For more information, visit www.silopharma.com and connect on social media at LinkedIn, X, and Facebook.
Silo Pharma (Nasdaq:SILO) has announced the development of SPC-15, a novel drug formulation targeting stress, anxiety, and PTSD. This initiative is part of a research agreement with Columbia University and aims to explore dose strengths and delivery methods for this potential treatment. Current research suggests that SPC-15 could effectively address cognitive impairment and other stress-related disorders. The drug's development aligns with alarming statistics: over 300 million people globally suffer from anxiety disorders, while approximately 12 million U.S. adults experience PTSD. The market for anxiety and depression treatments is projected to reach $13 billion by 2027. Additionally, Silo Pharma has secured a U.S. patent for SPC-15 as a treatment method for stress-induced disorders in females.
Silo Pharma (Nasdaq: SILO) announced the filing of a provisional patent for SP-26, aimed at pain management, targeting chronic pain conditions like fibromyalgia. This condition affects about 2% of the U.S. population and is characterized by widespread pain and cognitive issues. The patent application aligns with Silo's strategy to advance SP-26 towards an IND submission to the FDA, pursuing a 505(b)(2) regulatory pathway. The company holds several patents related to treatments for rare diseases and aims to address significant unmet needs in chronic pain therapy.
Silo Pharma, Inc. (Nasdaq: SILO) announced positive results from its toxicology study of SP-26, a novel time-released ketamine formulation. Conducted in collaboration with Experimur, the study employed a maximum feasibility dosing regimen in mini pigs, conforming to FDA standards. CEO Eric Weisblum emphasized that these outcomes are crucial for advancing toward human trials. The company plans to submit a Pre-Investigational New Drug (IND) package and pursue the FDA's 505(b)(2) regulatory pathway for drug approval. This marks a significant step for Silo in its mission to combine traditional therapeutics with psychedelic research for neurological disorders.
Silo Pharma has filed a provisional patent application for its novel homing peptides aimed at treating Alzheimer's disease and dementia. The company, devoted to merging traditional therapeutics with psychedelic research, emphasizes the need for effective treatment options for Alzheimer's, which involves significant cognitive decline and social deterioration. CEO Eric Weisblum highlighted hopes that targeted delivery of a therapeutic agent could enhance treatment outcomes. Silo Pharma is also exploring further applications of its CNS homing peptides alongside other preclinical studies.
Silo Pharma (Nasdaq: SILO) has received a U.S. Patent (11,491,120) for its drug SPC-15, aimed at treating and preventing stress-induced affective disorders such as anxiety and PTSD. This patent enhances the protection for their innovative treatment method, which utilizes ketamine compositions tailored for these disorders. The company has a commercial evaluation license agreement with Columbia University to potentially license related research assets, including treatments for Alzheimer’s disease. CEO Eric Weisblum emphasized the market potential and scope of the patent, further expanding Silo Pharma's intellectual property portfolio.
Silo Pharma, a developmental stage biopharmaceutical company, announced a share repurchase program authorized by its board to acquire up to $1,000,000 of its common stock. This program aims to enhance shareholder value amid favorable capital market conditions. As of November 10, 2022, the company had approximately 3,138,797 shares outstanding. The company may repurchase shares in the open market or via private transactions, contingent on market conditions and available liquidity. CEO Eric Weisblum emphasized the commitment to delivering value to shareholders through this initiative.
Silo Pharma (Nasdaq: SILO) announced a progress update on its clinical study at UCSF, which examines psilocybin as a treatment for conditions including Parkinson's disease, bipolar disorder, and chronic pain. The study involves therapy sessions with psilocybin and blood sample collection to analyze inflammatory activity. Data collection for Parkinson's patients is set to finish by February 2023, while bipolar and chronic pain studies are scheduled to commence in early and April 2023, respectively. The findings aim to shed light on psilocybin's therapeutic potential.
Silo Pharma has announced promising interim results from its study on SPU-21, a joint homing peptide aimed at treating rheumatoid arthritis. The latest phase demonstrated that the combination of SPU-21 with dexamethasone (DEX) showed superior effectiveness in controlling arthritis progression compared to DEX alone. This administration method is more preferred by patients, which could enhance market potential. The company is collaborating with the University of Maryland, Baltimore for further development.
Silo Pharma, Inc. (Nasdaq: SILO) released a shareholder letter detailing significant progress in its biopharmaceutical development, particularly in psychedelic research. The company reported having over $12 million in cash and no debt, positioning it to advance its pipeline projects. It highlighted multiple therapeutic candidates targeting conditions like fibromyalgia, multiple sclerosis, rheumatoid arthritis, and Alzheimer's disease. Furthermore, the burgeoning psychedelic drugs market is projected to grow from $2.8 billion in 2021 to $9.8 billion by 2029, emphasizing the potential of its unique technologies.
Silo Pharma, Inc. (Nasdaq: SILO) has initiated the initial dosing of its IND-enabling study for SP-26, a new time-released, topical ketamine formulation aimed at treating fibromyalgia. Conducted by Experimur, the study evaluates the tolerability of SP-26 to determine the maximum tolerated dose. With a market for fibromyalgia treatments projected to grow from $764 million in 2020 to $1.4 billion by 2027, this development could position Silo favorably. The company is also preparing a pre-IND submission to the FDA to pursue the 505(b)(2) regulatory pathway.
FAQ
What is the current stock price of Silo Pharma (SILO)?
What is the market cap of Silo Pharma (SILO)?
What does Silo Pharma, Inc. specialize in?
What are Silo Pharma's leading development programs?
Who are Silo Pharma's research partners?
What recent achievements has Silo Pharma announced?
How does Silo Pharma aim to impact the healthcare industry?
Where can I find more information about Silo Pharma?
What is the significance of Silo Pharma's SP-26 program?
What progress has been made with the SPC-15 program?
What conditions does Silo Pharma aim to address with its treatments?
How does Silo Pharma fund its research projects?
